The Food and Drug Administration suddenly decided to withdraw its emergency use authorization of two COVID-19 antibody treatments this week, leaving hundreds of patients who depend on them in the lurch.
The monoclonal antibody treatments made by Regeneron Pharmaceuticals and Eli Lilly have proven invaluable in fighting off hospitalization and death from the virus, especially against the delta variant. I would know: My grandmother was one of the patients in Florida who benefited from this treatment. Fully vaccinated and boosted, she tested positive for COVID-19 last month and was able to receive an antibody infusion within a few days. It improved her condition dramatically, and she has since recovered. But she might not have if she did not have access to this treatment.
Stay informed.Stay ahead.
Join Washington Examiner for unlimited access to the news, analysis, and commentary that matter most.
Already a member? Log in
